Skip to main content

Key Product Details

Species Reactivity

Validated:

SARS-CoV-2

Predicted:

SARS-CoV (93%). Backed by our 100% Guarantee.

Applications

ELISA, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Format

BSA Free

Concentration

1 mg/ml

Product Specifications

Immunogen

This antibody was raised against a peptide corresponding to 14 amino acids near the carboxyl terminus of SARS-CoV-2 (COVID-19) Envelope protein. The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Envelope protein.

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for SARS-CoV-2 Envelope Antibody - BSA Free

Western Blot: SARS-CoV-2 Envelope AntibodyBSA Free [NBP3-07060]

Western Blot: SARS-CoV-2 Envelope AntibodyBSA Free [NBP3-07060]

Western Blot: SARS-CoV-2 Envelope Antibody [NBP3-07060] - Loading: 50 ng per lane of SARS-CoV-2 (COVID-19) Envelope recombinant protein. Antibodies: SARS-CoV-2 (COVID-19) Envelope,1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 ug/mL and Lane 2: 2 ug/mL
Immunohistochemistry: SARS-CoV-2 Envelope Antibody - BSA Free [NBP3-07060]

Immunohistochemistry: SARS-CoV-2 Envelope Antibody - BSA Free [NBP3-07060]

Immunohistochemistry: SARS-CoV-2 Envelope Antibody [NBP3-07060] - Immunohistochemistry analysis of paraffin-embedded COVID-19 patient lung tissue using (0.5 ug/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 degrees celsius. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 envelope protein was observed in macrophage of COVID-19 patient lung, but not in non-COVID-19 patient lung.
ELISA: SARS-CoV-2 Envelope Antibody - BSA Free [NBP3-07060]

ELISA: SARS-CoV-2 Envelope Antibody - BSA Free [NBP3-07060]

ELISA: SARS-CoV-2 Envelope Antibody [NBP3-07060] - Antbodies: SARS-CoV-2 Envelope Antibody. A direct ELISA was performed using SARSCoV-2 Envelope recombinant protein (92-730) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Envelope antibody as the capture antibody. Secondary: Goat an-rabbit IgG HRP conjugate at 1:20000 diluon. Detection range is from 1 ng/mL to 3000 ng/mL

Applications for SARS-CoV-2 Envelope Antibody - BSA Free

Application
Recommended Usage

ELISA

1 ug/mL

Immunohistochemistry

0.5 ug/mL

Formulation, Preparation, and Storage

Purification

Peptide affinity purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: SARS-CoV-2 Envelope

The SARS-CoV-2 Envelope protein is one of the four major structural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1). The envelope protein is the smallest of the four structural proteins, which also includes the membrane protein, spike protein, and nucleocapsid protein (1,2). The envelope protein is synthesized as a 75 amino acid protein with a theoretical molecular weight of approximately 8.4 kDa (2,3). Furthermore, the envelope protein of SARS-CoV-2 has 94.7% sequence identity and 97.4% sequence similarity to the envelope protein of SARS-CoV (2). Structurally, the envelope protein is a membrane protein with a N-terminal domain, an alpha-helical transmembrane domain, and a hydrophilic C-terminal domain (1,4). The envelope protein has multiple functions in viral replication including viral assembly, release, and pathogenesis (2,4). Additionally, the SARS-CoV-2 envelope protein has ion channel activity and functions as a viroporin with a role in virion trafficking (2,4). Coronaviruses lacking the envelope protein are shown to have reduced viral titer and slowed or defective maturation, indicative of a role in virus production and growth (4).

References

1. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.

2. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The Protein Journal. https://doi.org/10.1007/s10930-020-09901-4

3. Uniprot (P0DTC4)

4. J Alsaadi, E. A., & Jones, I. M. (2019). Membrane binding proteins of coronaviruses. Future Virology. https://doi.org/10.2217/fvl-2018-0144

Alternate Names

2019-nCoV Envelope protein, COVID-19 Envelope protein, E Protein, Envelope, Human Coronavirus Envelope protein, SARSCoV2, SARS-CoV-2 E protein, SARSCoV2 Envelope protein, SARS-CoV-2 Envelope protein, Severe acute respiratory syndrome 2 Envelope Protein

Gene Symbol

E

Additional SARS-CoV-2 Envelope Products

Product Documents for SARS-CoV-2 Envelope Antibody - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for SARS-CoV-2 Envelope Antibody - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...